-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Sodium Phenylbutyrate + Taurursodiol) in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Sodium Phenylbutyrate + Taurursodiol) in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Sodium Phenylbutyrate + Taurursodiol) in Alzheimer's Disease Drug Details:Sodium phenylbutyrate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-6 in Acute Ischemic Stroke
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.GM-6 in Acute Ischemic Stroke Drug Details:GM-6 is under development for the treatment of amyotrophic lateral...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.(Sodium Phenylbutyrate + Taurursodiol) in Mild Cognitive ImpairmentDrug Details:Sodium...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pacritinib in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Chronic Myelomonocytic Leukemia (CMML) Drug Details: PacritInib...
-
Product Insights
Net Present Value Model: Albrioza
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Albrioza Drug Details Sodium phenylbutyrate and...
-
Product Insights
Net Present Value Model: Vonjo
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Vonjo Drug Details PacritInib (Vonjo) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (sodium phenylbutyrate + taurursodiol)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (sodium phenylbutyrate + taurursodiol) Drug Details Sodium phenylbutyrate and Taurursodiol (Albrioza, Relyvrio) is a...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – GM-6
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry GM-6 Drug Details GM-6 is under development for the treatment of amyotrophic lateral sclerosis,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – pacritinib
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry pacritinib Drug Details PacritInib (Vonjo) is an anti neoplastic agent. it is formulated as...
-
Product Insights
Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions. The Apoptosis regulator BAX - Drugs in Development research report provides a comprehensive overview on the therapeutics under development...